Eckert & Ziegler SE (EKZRF) Q1 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Berlin-based Eckert & Ziegler SE reported first-quarter results that showed continued momentum in its core medical operations despite currency pressures. The company’s overall sales reached 72.95 million euros, up from 68.19 million euros a year earlier. Net income rose to 10.37 million euros, supporting basic earnings per share of 0.17 euros. Management described the outcome as confirmation that its long-term strategy remains on track.
Medical Division Leads the Way
The medical segment delivered the strongest contribution, posting revenue growth above 20 percent. This performance helped offset softer results elsewhere and underscored demand for the company’s isotope-based products used in cancer diagnostics and therapy. Executives noted that recurring orders from established hospital networks provided a stable base during the period.
Service revenue declined, partly because a large licensing agreement recorded in the prior year did not repeat. Currency effects, especially a weaker U.S. dollar, further reduced reported figures when translated back to euros. Adjusted for these factors, underlying business activity remained positive.
Isotope Segment Faces Headwinds
Revenue in the isotope division fell roughly 7 percent year over year. The drop reflected both lower volumes in certain product lines and the impact of exchange-rate movements. Management indicated that recent investments in production capacity should support a recovery once demand normalizes.
Despite the quarterly dip, the division continues to supply critical materials for industrial and medical applications worldwide. Company leaders emphasized ongoing efforts to diversify customer contracts and reduce exposure to single markets.
Key Figures at a Glance
- Sales: 72.95 million euros (up 7 percent)
- Net income: 10.37 million euros (up from 9.69 million euros)
- Basic EPS: 0.17 euros (up from 0.16 euros)
- Medical division growth: more than 20 percent
- Isotope division revenue: down 7 percent
Outlook and Next Steps
Executives reiterated confidence in full-year targets, citing a solid order backlog and expanding clinical use of their technologies. They plan to maintain investment levels in research and manufacturing while monitoring currency trends closely. Investors will watch upcoming quarters for signs that isotope volumes stabilize and medical momentum continues.
The results arrive at a time when healthcare providers increasingly rely on precise isotope solutions for both diagnosis and treatment. Eckert & Ziegler’s ability to meet that demand positions it for further growth even as external factors create short-term variability.